Redmile Exits IGMS Holdings After $1.247/Share Acquisition with CVR Rights
Rhea-AI Filing Summary
IGM Biosciences was acquired in a transaction where holders received $1.247 per share in cash plus one contingent value right (CVR) per share. The acquiring parent completed a tender offer and the subsequent merger, after which outstanding common stock, non-voting common stock and pre-funded warrants held by reporting persons were cancelled for cash consideration and CVRs based on the transaction terms. Reported Redmile-managed funds and Jeremy Green disclosed disposition of their beneficial interests, resulting in zero beneficial ownership reported post-transaction. A Redmile managing director resigned from the issuer's board immediately prior to the merger closing.
Positive
- Completed merger providing immediate cash consideration of $1.247 per share to outstanding holders
- Contingent Value Rights (CVRs) granted per share, offering potential additional upside beyond the cash price
- Cancellation of pre-funded warrants for cash and CVRs simplified post-transaction capital structure
Negative
- Reporting persons (Redmile-managed funds and Jeremy Green) disposed of all reported holdings, now reporting 0 shares beneficially owned
- Board change: Michael Lee resigned as a director immediately prior to the merger closing, reducing prior independent representation
Insights
TL;DR: The merger delivered a cash exit of $1.247 per share plus CVRs; significant insiders fully divested their positions.
The transaction represents a full liquidity event for public holders: a fixed cash price of $1.247 per share coupled with a CVR that may provide additional contingent value. Redmile-managed vehicles and Jeremy Green reported disposing of all reported common, non-voting common and pre-funded warrant positions, reporting 0 shares beneficially owned after the closing. For valuation analysis, investors should treat the cash consideration as the guaranteed component and the CVR as contingent upside; the elimination of outstanding warrants and conversion mechanics simplified the capital structure post-closing.
TL;DR: Governance changed as the company became a wholly owned subsidiary and a Redmile director resigned before closing.
The merger converted the public issuer into a private subsidiary, removing the company from public governance processes and market oversight. Reported departures include the resignation of Michael Lee from the board immediately prior to closing, indicating pre-closing board alignment with the transaction. The Form 4 discloses that reported securities were held via Redmile funds and may have been deemed beneficially owned by Jeremy Green, who now reports no remaining beneficial holdings. These are material governance changes for any remaining stakeholders tied to the CVR arrangements.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Non-Voting Common Stock | 7,199,325 | $0.00 | -- |
| Disposition | Pre-Funded Warrants to Purchase Common Stock | 667,666 | $0.00 | -- |
| Disposition | Common Stock | 2,964,843 | $0.00 | -- |
Footnotes (1)
- On August 14, 2025, pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 1, 2025, among the Issuer, Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer to purchase all outstanding shares of the Issuer's Common Stock and Non-Voting Common Stock ("Issuer Shares") in exchange for (a) a price per share of $1.247 in cash (the "Offer Price"), subject to applicable tax withholding and without interest, plus (b) one contingent value right ("CVR") per share subject to the terms and conditions of a Contingent Value Rights Agreement ("CVR Agreement"). The tender offer expired one minute following 11:59 p.m., Eastern Time, on August 13, 2025 (the "Offer Closing"). On August 14, 2025, the Issuer completed its merger transaction with and into Merger Sub pursuant to the terms of the Merger Agreement, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). At the effective date and time of the Merger (the "Merger Closing"), each outstanding and unexercised pre-funded warrant to purchase shares of the Issuer's Common Stock (each, a "Pre-Funded Warrant") was cancelled and the holder received the right to a cash amount based on the Offer Price, subject to applicable tax withholding and without interest, less the exercise price per share underlying the Pre-Funded Warrant, plus one CVR per underlying share subject to the terms and conditions of a CVR Agreement. The Non-Voting Common Stock was convertible into shares of the Issuer's common stock at any time, in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time and from time to time at the holder's election on a 1-for-1 basis. The Non-Voting Common Stock had no expiration date. The Pre-Funded Warrants to purchase common stock of the Issuer have no expiration date. The Common Stock, Non-Voting Common Stock, and Pre-Funded Warrants of the Issuer reported herein were directly owned by certain private investment vehicles managed by Redmile (each, a "Redmile Fund"), and may have been deemed beneficially owned by Redmile as investment manager of the Redmile Funds. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile (collectively with Redmile, the "Reporting Persons"). The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, if any, and this Form 4 shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
